Iota carrageenan bulk9/15/2023 ![]() ![]() ![]() Ministerio de Ciencia, Tecnología e Innovación, Argentina Freely provided drug and placebo samples from Laboratorio Pablo Cassará, during the conduct of the study personal fees from Laboratorio Pablo Cassará, outside the submitted work Dr Mónica Lombardo report personal fees from Laboratorio Pablo Cassará, outside the submitted work, is a Director of Scientific Affairs at Nobeltri S.R.L Dr Robert Giugliano report personal fees from Astra Zeneca, personal fees from CVS Caremark, personal fees from Pfizer, personal fees from Novartis, outside the submitted work and Institutional research grant to the TIMI Study Group at Brigham and Women’s Hospital for research he is not directly involved in from Abbott Aralez AstraZeneca Bayer Eisai GlaxoSmithKline Intarcia Janssen Research and Development Medicines Company MedImmune Novartis Poxel Pfizer Quark Pharmaceuticals Roche Takeda Zora Biosciences. In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease.ĬOVID-19 hospital workers nasal prophylaxis spray.ĭr Juan Manuel Figueroa report grantfrom Programa de articulación y fortalecimiento federal de las capacidades en ciencia y tecnología COVID-19, Proyecto CABA 20. Absolute risk reduction: 4% (95% CI 0.6 to 7.4). The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 ) and those receiving placebo (10 of 198 ). Both treatment groups had similar baseline characteristics. The trial is registered at ( NCT04521322).Ī total of 394 individuals were randomly assigned to receive I-C or placebo. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture.Ĭan a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. 18 Institute of Physiology, Molecular Biology and Neurosciences, Buenos Aires University-CONICET, Ciudad Autónoma de Buenos Aires, Argentina.17 Cell Biology and Neurosciences Institute (IBCN), Buenos Aires University-CONICET, Ciudad Autónoma de Buenos Aires, Argentina. ![]() Teodoro Alvarez, Ciudad Autónoma de Buenos Aires, Argentina. 16 Department of Family Medicine, Hospital Gral.15 Medical Direction, Clínica Modelo De Morón, Morón, Provincia de Buenos Aires, Argentina.14 Pulmonology Department, Hospital 4 de Junio Dr Ramón Carrillo, Chaco, Argentina.13 Department of Medicine, Clínica Monte Grande, Monte Grande, Buenos Aires, Argentina.12 Pulmonology Department, Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.11 Pulmonology Department, Hospital Pediátrico Avelino Castelán, Resistencia, Chaco, Argentina.Perón, Avellaneda, Buenos Aires, Argentina. 10 Medical Direction Department, Hospital Interzonal de Agudos Pte.9 Otolaryngology Department, Clínica y Maternidad Santa Isabel, Ciudad Autónoma de Buenos Aires, Argentina.8 Intensive Care Department, Sanatorio Parque de Rosario, Rosario, Santa Fe, Argentina.7 Département de Médecine, Université de Montréal and Centre d'études avancées en médecine du sommeil, Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada.6 Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, MA, USA.5 Department of Infectology, Sanatorio de Niños de Rosario, Rosario, Santa Fe, Argentina.4 Department of Cardiology, Instituto Cardiovascular de Rosario, Rosario, Santa Fe, Argentina.3 Scientific Direction, Nobeltri S.R.L, Ciudad Autónoma de Buenos Aires, Argentina.2 Clinical Research Unit, Hospital Universitario CEMIC, Ciudad Autónoma de Buenos Aires, Argentina.1 Sleep and Respiratory Research Center, Instituto de Ciencia y Tecnología Cesar Milstein, Ciudad Autónoma de Buenos Aires, Argentina. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |